J&J Medical Connect
DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Medical Information

Storage and Stability of DARZALEX FASPRO Vials at Freezing Temperatures

Last Updated: 09/23/2025

SUMMARY  

  • Please refer to local prescribing information for storage and stability information.
  • Janssen cannot recommend any practices, procedures, or storage conditions that deviate from product labeling and are not approved by the regulatory agencies.

STABILITY AND TEMPERATURE EXCURSION DATA

  • For shelf-life of unopened DARZALEX FASPRO vials see expiry date on the outer pack.1
  • Stability studies support specified expiration dating period for DARZALEX FASPRO vials when stored at 2°C to 8°C (36°F to 46°F) and protected from direct sunlight, with excursions permitted between -20°C to 1°C (-4°F to 34°F) for up to 9 days cumulative excursions, in no more than 3 excursions (3 days each).1,2
  • This data was collected in a strictly controlled environment. The response above provides information on a specific scenario for which we have data. If there is no tracking of time and temperature, Janssen cannot provide recommendations.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 18 September 2025.

 

References

1 Data on File. Daratumumab Subcutaneous Formulation Company Core Data Sheet (CCDS). Janssen Research & Development, LLC. EDMS-ERI-184804517; 2025.  
2 Data on File. Daratumumab Gen2 DP SC (1800 mg/vial) Commercial Expiry and Temperature Excursion Memo. TV-TEC-71555; 2025.